An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease

阿尔茨海默病中淀粉样蛋白、tau蛋白和炎症病理生理学之间关系的综合分析

阅读:2

Abstract

Alzheimer's disease (AD) research is a large and burgeoning field, where varied methodological approaches are providing multifaceted, but sometimes contradictory, views on the etiology and progression of pathology. The current review aims to summarize and integrate these findings to provide greater coherence to an increasingly splintered field. We provide an overview of the findings from each subfield (neuropathology, positron emission tomography imaging, fluid biomarkers, genetics, transcriptomics/proteomics), highlighting the strengths and weaknesses of each approach and, where possible, trying to resolve discrepancies between subfields. In particular, we address arguments about whether amyloid versus tau initiates pathology, and integrate nanoscale data from aging macaques to improve clarity regarding the earliest pathological stages, as initial phosphorylation events can be lost post mortem in human tissue. We find that Aβ(42), phosphorylated tau, and inflammation/excessive calcium can all interact in feedforward cycles to drive AD pathology. Increasing cohesion across subdisciplines will strengthen our understanding of this devastating disease. HIGHLIGHTS: AD research is an expansive field, where subfields often diverge. The current review integrates across approaches to give a more cohesive view. Many methods cannot detect the earliest changes in brain. The new fluid biomarker pT217Tau shows that soluble tau pathology begins early. Relating amyloid/tau pathologies to inflammation is key for understanding sporadic AD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。